Anoro Ellipta, a medication used to treat chronic obstructive pulmonary disease (COPD), does not currently have a generic version available in the United States [1]. The medication is manufactured by GlaxoSmithKline [2].
When could a generic Anoro Ellipta become available?
The availability of generic Anoro Ellipta depends on patent expirations and any potential legal challenges to those patents. Information regarding the specific patent landscape for Anoro Ellipta can be found on resources like DrugPatentWatch.com [3].
What are the active ingredients in Anoro Ellipta?
Anoro Ellipta contains two active ingredients: umeclidinium and vilanterol [4]. Umeclidinium is a long-acting muscarinic antagonist (LAMA), and vilanterol is a long-acting beta2-adrenergic agonist (LABA) [4]. These two bronchodilators work together to help keep the airways open [4].
How is Anoro Ellipta administered?
Anoro Ellipta is delivered via an inhaler device called Ellipta [5]. Patients inhale the medication once daily [5].
What are the approved uses for Anoro Ellipta?
Anoro Ellipta is indicated for the long-term, once-daily maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema [4]. It is not intended for the relief of acute bronchospasm [4].
What are the potential side effects of Anoro Ellipta?
Common side effects of Anoro Ellipta can include cold-like symptoms, increased blood pressure, mouth pain, and urinary tract infections [6]. More serious side effects may involve paradoxical bronchospasm, worsening angle-closure glaucoma, and urinary retention [6].
What is the cost of Anoro Ellipta?
The cost of Anoro Ellipta can vary depending on insurance coverage and pharmacy. Patients may explore savings programs offered by the manufacturer or look into patient assistance programs if they face financial challenges [7].
What are alternative COPD treatments?
Other bronchodilators, including other LAMAs and LABAs, as well as combination inhalers, are available for COPD management. These may include medications like tiotropium, salmeterol, and fluticasone propionate [8].
What are the challenges in developing generic respiratory inhalers?
Developing generic versions of inhaled medications, such as Anoro Ellipta, presents unique challenges. These include demonstrating bioequivalence, replicating the complex device technology, and navigating the regulatory pathway [9].
---
Sources:
1. https://www.accessdata.fda.gov/scripts/cder/ob/default.cfm
2. https://www.gsksource.com/pharma/content/gsksource/us/en_us/brands/anoro.html
3. https://drugpatentwatch.com/
4. https://www.anoroellipta.com/
5. https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients/anoro-ellipta-uticas-drug-safety-communication-fda-approved-labeling-changes-related-potential-risks
6. https://www.mayoclinic.org/drugs-supplements/umeclidinium-and-vilanterol-inhalation-route/side-effects/dr20069189
7. https://www.anoroellipta.com/savings-and-support/
8. https://www.uptodate.com/contents/approach-to-the-patient-with-copd-beyond-the-basics
9. https://www.fda.gov/drugs/abbreviated-new-drug-applications-andas/generics-inhalers-and-nasal-sprays